研究者業績

樋口 佳則

ヒグチ ヨシノリ  (Yoshinori Higuchi)

基本情報

所属
千葉大学 大学院医学研究院中核研究部門 脳・神経治療学研究講座 教授 (博士(医学))
学位
博士(医学)(2000年3月 千葉大学)

連絡先
yhiguchifaculty.chiba-u.jp
研究者番号
00456055
ORCID ID
 https://orcid.org/0000-0001-5689-3416
J-GLOBAL ID
201901020976060837
researchmap会員ID
B000368287

学歴

 2

主要な論文

 213
  • Alfonso Fasano, Hideo Mure, Genko Oyama, Nagako Murase, Thomas Witt, Yoshinori Higuchi, Alexa Singer, Claudia Sannelli, Nathan Morelli
    Neurobiology of Disease 199 106589-106589 2024年9月  査読有り
  • Tomohiro Yamaki, Maidinamu Yakufujiang, Nobuo Oka, Daisuke Ito, Masaru Odaki, Shigeki Kobayashi, Yoshinori Higuchi
    Brain Disorders 13 100123 2024年2月  査読有り最終著者責任著者
  • Chad G Rusthoven, Alyse W Staley, Dexiang Gao, Shoji Yomo, Denise Bernhardt, Narine Wandrey, Rami El Shafie, Anna Kraemer, Oscar Padilla, Veronica Chiang, Andrew M Faramand, Joshua D Palmer, Brad E Zacharia, Rodney E Wegner, Jona A Hattangadi-Gluth, Antonin Levy, Kenneth Bernstein, David Mathieu, Daniel N Cagney, Michael D Chan, Inga S Grills, Steve Braunstein, Cheng-Chia Lee, Jason P Sheehan, Christien Kluwe, Samir Patel, Lia M Halasz, Nicolaus Andratschke, Christopher P Deibert, Vivek Verma, Daniel M Trifiletti, Christopher P Cifarelli, Jürgen Debus, Stephanie E Combs, Yasunori Sato, Yoshinori Higuchi, Kyoko Aoyagi, Paul D Brown, Vida Alami, Ajay Niranjan, L Dade Lunsford, Douglas Kondziolka, D Ross Camidge, Brian D Kavanagh, Tyler P Robin, Toru Serizawa, Masaaki Yamamoto
    Journal of the National Cancer Institute 2023年5月4日  査読有り
    INTRODUCTION: Historical reservations regarding radiosurgery (SRS) for small-cell-lung-cancer (SCLC) brain metastases (BrM) include concerns for short-interval/diffuse CNS-progression, poor prognoses, and increased neurological mortality specific to SCLC histology. We compared SRS outcomes for SCLC and non-small-cell-lung-cancer (NSCLC) where SRS is well established. METHODS: Multicenter first-line SRS outcomes for SCLC and NSCLC from 2000-2022 were retrospectively collected (N=892-SCLC/N=4,785-NSCLC). Data from the prospective JLGK0901 SRS trial were analyzed as a comparison cohort (N=98-SCLC/N=794-NSCLC). OS and CNS-progression were analyzed using Cox-Proportional-Hazard and Fine-Gray models, respectively, with multivariable (MV) adjustment (including age/sex/performance-status/year/extracranial disease/BrM-number/BrM-volume). Mutation-stratified analyses were performed in propensity score-matched (PSM) retrospective cohorts of EGFR/ALK-positive-NSCLC, mutation-negative-NSCLC, and SCLC. RESULTS: OS was superior with NSCLC over SCLC in the retrospective dataset (median-OS, 10.5 vs 8.6 months, MV-p<0.001) and JLGK0901. Hazard estimates for first CNS-progression favoring NSCLC were similar in both datasets but reached significance in the retrospective dataset only (MV-HR:0.82 [95%-CI:0.73-0.92], p=0.001). In the PSM cohorts, there were continued OS advantages for NSCLC (median-OS, 23.7 [EGFR/ALK-positive-NSCLC] vs 13.6 [mutation-negative-NSCLC] vs 10.4 months [SCLC], pairwise-p-values<0.001), but no significant differences in CNS-progression. Neurological mortality and number of lesions at CNS-progression were similar for NSCLC and SCLC patients. Leptomeningeal-progression was increased in NSCLC patients in the retrospective dataset only (MV-HR:1.61 [95%-CI:1.14-2.26], p=0.007). CONCLUSION: After SRS, SCLC was associated with shorter OS compared to NSCLC. CNS progression occurred earlier in SCLC overall but was similar in patients matched on baseline characteristics. Neurological mortality, lesions at CNS-progression, and leptomeningeal-progression were comparable. These findings may better inform clinical decision-making for SCLC patients.
  • Yoshinori Higuchi, Shigeki Nakano, Kyoko Aoyagi, Shinichi Origuchi, Kentaro Horiguchi, Toru Serizawa, Iwao Yamakami, Yasuo Iwadate
    Journal of Neurosurgery 1-9 2022年12月1日  査読有り筆頭著者責任著者
    OBJECTIVE Due to the heterogeneous definitions of tumor regrowth and various tumor volume distributions, the nature of small remnants after vestibular schwannoma (VS) surgery and the appropriate timing of adjuvant stereotactic radiosurgery for these remnants remain unclear. In this study, the growth potential of small remnants (&lt; 1 cm3) after VS surgery was compared with that of treatment-naïve (TN) small VSs. METHODS This retrospective single-center study included 44 patients with VS remnants following subtotal resection (STR) of a large VS (remnant group) and 75 patients with TN VS (&lt; 1 cm3; TN group). A 20% change in tumor volume over the imaging interval indicated radiographic progression or regression. Tumor progression-free survival (TPFS) rates were estimated using the Kaplan-Meier method. RESULTS In the remnant group, the mean preoperative tumor volume was 13.8 ± 9.0 cm3 and the mean tumor resection rate was 95% ± 5%. The mean tumor volume at the start of the observation period did not differ significantly between the two groups (remnant vs TN: 0.41 ± 0.29 vs 0.34 ± 0.28 cm3, p = 0.171). The median periods until tumor progression was detected were 15.1 (range 4.9–76.2) months and 44.7 (range 12.6–93.2) months in the TN and remnant groups, respectively. In the remnant group, the TPFS rates were 74% and 70% at 3 and 5 years after the surgery, respectively, compared with 59% and 47% in the TN group. The log-rank test demonstrated a significant difference (p = 0.008) in the TPFS rates between the two groups. Furthermore, 42 patients each from the remnant and TN groups were matched based on tumor volume. TPFS was significantly longer in the remnant group than in the TN group (3-year rates, 77% vs 62%; 5-year rates, 73% vs 51%; p = 0.02). In the remnant group, 18% of the tumor remnants demonstrated regression during follow-up, compared with 9% in the TN group, but this intergroup difference was not significant (p = 0.25). CONCLUSIONS This study demonstrated that the growth potential of small VS remnants was lower than that of TN tumors. Observing for small remnants may be appropriate after STR of a large VS. Given the risk of tumor regrowth, careful observation using MRI should be mandatory during follow-up.
  • Yoshinori Higuchi, Shiro Ikegami, Kentaro Horiguchi, Kyoko Aoyagi, Osamu Nagano, Toru Serizawa, Yosuke Tajima, Toyoyuki Hanazawa, Iwao Yamakami, Yasuo Iwadate
    World neurosurgery 148 e406-e414 2021年4月  査読有り筆頭著者責任著者
    OBJECTIVE: The relationship between quantitative posturography results and growth of vestibular schwannomas (VSs) during conservative management has not been studied. We aimed to clarify the relationship between the presence of disequilibrium based on posturographic measurement and VS growth. METHODS: This retrospective, single-center study included 53 patients with VSs (Koos stage I or II) managed conservatively after initial diagnosis. Radiographic progression was considered present if 20% volumetric growth was observed over the imaging interval. Posturography was performed at initial diagnosis, and sway velocity (SV) and sway area were calculated. Tumor growth-free survival was estimated using the Kaplan-Meier method. RESULTS: Mean follow-up period was 2.87 ± 2.58 years, up to tumor growth detection or last follow-up magnetic resonance imaging. Tumor growth incidence was 40.8% and 61.2% at 2 and 5 years, respectively. Cerebellopontine angle extension and SV with eyes open were related to tumor growth. Tumor growth-free survival of patients with cerebellopontine angle extension and patients with intracanalicular tumor at 2 years was 37.3% and 76.4%, respectively. Tumor growth-free survival of patients with SV >2.06 cm/second and patients with SV ≤2.06 cm/second at 2 years was 30.8% and 68.9%, respectively. The Cox hazard model demonstrated a significant risk for future tumor growth with SV >2.06 cm/second (relative risk, 2.475; 95% confidence interval, 1.11-5.37, P = 0.027). CONCLUSIONS: We demonstrated a positive correlation between SV with eyes open and future tumor growth. Posturographic data are objective and quantitative; thus, SV may be a potential predictor of future growth of VSs.
  • Maidinamu Yakufujiang, Yoshinori Higuchi, Kyoko Aoyagi, Tatsuya Yamamoto, Toru Sakurai, Midori Abe, Yoji Okahara, Masaki Izumi, Osamu Nagano, Yoshitaka Yamanaka, Shigeki Hirano, Akihiro Shiina, Atsushi Murata, Yasuo Iwadate
    World neurosurgery 147 e428-e436 2021年3月  査読有り責任著者
    OBJECTIVE: Deep brain stimulation (DBS) of the bilateral subthalamic nucleus (STN) is a standard surgical treatment option in patients with advanced Parkinson's disease. Adverse effects on cognitive function have been reported, impacting the quality of life of patients and caregivers. We aimed to investigate a quantitative predictive preexisting cognitive factor for predicting postoperative cognitive changes. METHODS: Thirty-five patients underwent STN-DBS. A battery of neuropsychological tests were used to examine executive function, processing speed, and visuospatial function both preoperatively and 1 year postoperatively. A multiple logistic regression analysis was performed to investigate the relationships between preoperative factors and cognitive outcomes. The predictive value of the preoperative factors for global cognitive decline during long-term follow-up were evaluated. RESULTS: The patients exhibited significant changes in processing speed and visuospatial function after surgery. Using reliable change index values, lower preoperative scores on the Similarities and Object Assembly subtests of the Wechsler Adult Intelligence Scale III were associated with decreases in visuospatial function at 1 year after DBS. The odds ratios were 10.2 for Similarities and 9.53 for Object Assembly. The proportion of Mini Mental State Examination-maintained patients with low scores on the Similarities subtest was significantly lower than that of patients with high scores at 3 and 5 years. No factors were found to be related to decreases in processing speed. CONCLUSIONS: Preoperative evaluation of the Similarities and Object Assembly subtests may be useful to identify patients who are at a greater risk of experiencing decreases in visuospatial functioning after STN-DBS. Furthermore, a low score on the Similarities subtest may predict future global cognitive deterioration.
  • Weibing Liu, Tatsuya Yamamoto, Yoshitaka Yamanaka, Masato Asahina, Tomoyuki Uchiyama, Shigeki Hirano, Keisuke Shimizu, Yoshinori Higuchi, Satoshi Kuwabara
    Frontiers in neurology 12 656041-656041 2021年  査読有り
    Background: Indications for subthalamic nucleus deep brain stimulation (STN-DBS) surgery are determined basically by preoperative motor function; however, postoperative quality of life (QOL) is not necessarily associated with improvements in motor symptoms, suggesting that neuropsychiatric symptoms might be related to QOL after surgery in patients with Parkinson's disease. Objectives: We aimed to examine temporal changes in neuropsychiatric symptoms and their associations with QOL after STN-DBS. Materials and Methods: We prospectively enrolled a total of 61 patients with Parkinson's disease (mean age = 65.3 ± 0.9 years, mean disease duration = 11.9 ± 0.4 years). Motor function, cognitive function, and neuropsychiatric symptoms were evaluated before and after DBS surgery. Postoperative evaluation was performed at 3 months, 1 year, and 3 years after surgery. Results: Of the 61 participants, 54 completed postoperative clinical evaluation after 3 months, 47 after 1 year, and 23 after 3 years. Frontal lobe functions, depression, and verbal fluency significantly worsened 3 years after STN-DBS. Non-motor symptoms such as impulsivity and the Unified PD Rating Scale (UPDRS) part I score were associated with QOL after STN-DBS. Conclusions: Frontal lobe functions, depression, and verbal fluency significantly worsened 3 years after STN-DBS. The UPDRS part I score and higher impulsivity might be associated with QOL after STN-DBS.
  • Kyoko Aoyagi, Yoshinori Higuchi, Shigeo Matsunaga, Toru Serizawa, Shoji Yomo, Hitoshi Aiyama, Osamu Nagano, Takeshi Kondoh, Hiroyuki Kenai, Takashi Shuto, Jun Kawagishi, Hidefumi Jokura, Sonomi Sato, Kiyoshi Nakazaki, Kotaro Nakaya, Toshinori Hasegawa, Mariko Kawashima, Hideya Kawai, Kazuhiro Yamanaka, Yasushi Nagatomo, Masaaki Yamamoto, Yasunori Sato, Tomoyoshi Aoyagi, Tomoo Matsutani, Yasuo Iwadate
    Breast cancer research and treatment 184(1) 149-159 2020年11月  査読有り責任著者
    INTRODUCTION: Brain metastasis (BM) is one of the most important issues in the management of breast cancer (BC), since BMs are associated with neurological deficits. However, the importance of BC subtypes remains unclear for BM treated with Gamma Knife radiosurgery (GKS). Thus, we conducted a multicenter retrospective study to compare clinical outcomes based on BC subtypes, with the aim of developing an optimal treatment strategy. METHODS: We studied 439 patients with breast cancer and 1-10 BM from 16 GKS facilities in Japan. Overall survival (OS) was analyzed by the Kaplan-Meier method, and cumulative incidences of systemic death (SD), neurologic death (ND), and tumor progression were estimated by competing risk analysis. RESULTS: OS differed among subtypes. The median OS time (months) after GKS was 10.4 in triple-negative (TN), 13.7 in Luminal, 31.4 in HER2, and 35.8 in Luminal-HER2 subtype BC (p < 0.0001). On multivariate analysis, poor control of the primary disease (hazard ratio [HR] = 1.84, p < 0.0001), active extracranial disease (HR = 2.76, p < 0.0001), neurological symptoms (HR 1.44, p = 0.01), and HER2 negativity (HR = 2.66, p < 0.0001) were significantly associated with worse OS. HER2 positivity was an independent risk factor for local recurrence (p = 0.03) but associated with lower rates of ND (p = 0.03). TN histology was associated with higher rates of distant brain failure (p = 0.03). CONCLUSIONS: HER2 positivity is related to the longer OS after SRS; however, we should pay attention to preventing recurrence in Luminal-HER2 patients. Also, TN patients require meticulous follow-up observation to detect distant metastases and/or LMD.
  • Chad G Rusthoven, Masaaki Yamamoto, Denise Bernhardt, Derek E Smith, Dexiang Gao, Toru Serizawa, Shoji Yomo, Hitoshi Aiyama, Yoshinori Higuchi, Takashi Shuto, Atsuya Akabane, Yasunori Sato, Ajay Niranjan, Andrew M Faramand, L Dade Lunsford, James McInerney, Leonard C Tuanquin, Brad E Zacharia, Veronica Chiang, Charu Singh, James B Yu, Steve Braunstein, David Mathieu, Charles J Touchette, Cheng-Chia Lee, Huai-Che Yang, Ayal A Aizer, Daniel N Cagney, Michael D Chan, Douglas Kondziolka, Kenneth Bernstein, Joshua S Silverman, Inga S Grills, Zaid A Siddiqui, Justin C Yuan, Jason P Sheehan, Diogo Cordeiro, Kename Nosaki, Takahashi Seto, Christopher P Deibert, Vivek Verma, Samuel Day, Lia M Halasz, Ronald E Warnick, Daniel M Trifiletti, Joshua D Palmer, Albert Attia, Benjamin Li, Christopher P Cifarelli, Paul D Brown, John A Vargo, Stephanie E Combs, Kerstin A Kessel, Stefan Rieken, Samir Patel, Matthias Guckenberger, Nicolaus Andratschke, Brian D Kavanagh, Tyler P Robin
    JAMA oncology 6(7) 1028-1037 2020年7月1日  査読有り
    Importance: Although stereotactic radiosurgery (SRS) is preferred for limited brain metastases from most histologies, whole-brain radiotherapy (WBRT) has remained the standard of care for patients with small cell lung cancer. Data on SRS are limited. Objective: To characterize and compare first-line SRS outcomes (without prior WBRT or prophylactic cranial irradiation) with those of first-line WBRT. Design, Setting, and Participants: FIRE-SCLC (First-line Radiosurgery for Small-Cell Lung Cancer) was a multicenter cohort study that analyzed SRS outcomes from 28 centers and a single-arm trial and compared these data with outcomes from a first-line WBRT cohort. Data were collected from October 26, 2017, to August 15, 2019, and analyzed from August 16, 2019, to November 6, 2019. Interventions: SRS and WBRT for small cell lung cancer brain metastases. Main Outcomes and Measures: Overall survival, time to central nervous system progression (TTCP), and central nervous system (CNS) progression-free survival (PFS) after SRS were evaluated and compared with WBRT outcomes, with adjustment for performance status, number of brain metastases, synchronicity, age, sex, and treatment year in multivariable and propensity score-matched analyses. Results: In total, 710 patients (median [interquartile range] age, 68.5 [62-74] years; 531 men [74.8%]) who received SRS between 1994 and 2018 were analyzed. The median overall survival was 8.5 months, the median TTCP was 8.1 months, and the median CNS PFS was 5.0 months. When stratified by the number of brain metastases treated, the median overall survival was 11.0 months (95% CI, 8.9-13.4) for 1 lesion, 8.7 months (95% CI, 7.7-10.4) for 2 to 4 lesions, 8.0 months (95% CI, 6.4-9.6) for 5 to 10 lesions, and 5.5 months (95% CI, 4.3-7.6) for 11 or more lesions. Competing risk estimates were 7.0% (95% CI, 4.9%-9.2%) for local failures at 12 months and 41.6% (95% CI, 37.6%-45.7%) for distant CNS failures at 12 months. Leptomeningeal progression (46 of 425 patients [10.8%] with available data) and neurological mortality (80 of 647 patients [12.4%] with available data) were uncommon. On propensity score-matched analyses comparing SRS with WBRT, WBRT was associated with improved TTCP (hazard ratio, 0.38; 95% CI, 0.26-0.55; P < .001), without an improvement in overall survival (median, 6.5 months [95% CI, 5.5-8.0] for SRS vs 5.2 months [95% CI, 4.4-6.7] for WBRT; P = .003) or CNS PFS (median, 4.0 months for SRS vs 3.8 months for WBRT; P = .79). Multivariable analyses comparing SRS and WBRT, including subset analyses controlling for extracranial metastases and extracranial disease control status, demonstrated similar results. Conclusions and Relevance: Results of this study suggest that the primary trade-offs associated with SRS without WBRT, including a shorter TTCP without a decrease in overall survival, are similar to those observed in settings in which SRS is already established.
  • Masaaki Yamamoto, Toru Serizawa, Osamu Nagano, Kyoko Aoyagi, Yoshinori Higuchi, Yasunori Sato, Hidetoshi Kasuya, Bierta E Barfod
    Journal of neuro-oncology 147(1) 177-184 2020年3月  査読有り
    PURPOSE: This study aimed to validate whether the recently-proposed prognostic grading system, initial brain metastasis velocity (iBMV), is applicable to breast cancer patients receiving stereotactic radiosurgery (SRS). We focused particularly on whether this grading system is useful for patients with all molecular types, i.e., positive versus negative for EsR, PgR and HER2. METHODS AND MATERIALS: This was an institutional review board-approved, retrospective cohort study using our database, prospectively accumulated at three gamma knife institutes, during the 20-year-period since 1998. We excluded patients for whom the day of primary cancer diagnosis was not available, had synchronous presentation, lacked information regarding molecular types, and/or had received pre-SRS radiotherapy and/or surgery. We ultimately studied 511 patients categorized into two classes by iBMV scores, i.e., < 2.00 and ≥ 2.00. RESULTS: The median iBMV score for the entire cohort was 0.97 (IQR 0.39-2.84). Median survival time (MST) in patients with iBMV < 2.00, 15.9 (95% CI 13.0-18.6, IQR 7.5-35.5) months, was significantly longer than that in patients with iBMV ≥ 2.00, 8.2 (95% CI 6.8-9.9, IQR 3.9-19.4) months (HR 1.582, 95% CI: 1.308-1.915, p < 0.0001). The same results were obtained in patients with EsR (-), PgR (-), HER2 (+) and HER2 (-) cancers, while MSTs did not differ significantly between iBMV < 2.00 vs ≥ 2.00 in patients with EsR (+) and PgR (+) cancers. CONCLUSIONS: This system was clearly shown to be applicable to breast cancer patients with SRS-treated BMs. However, this system is not applicable to patients with hormone receptor (+) breast cancer.
  • Daisuke Ito, Kyoko Aoyagi, Osamu Nagano, Toru Serizawa, Yasuo Iwadate, Yoshinori Higuchi
    Journal of neuro-oncology 147(1) 237-246 2020年3月  査読有り最終著者
    PURPOSE: Stereotactic radiosurgery (SRS) is typically considered for patients who cannot undergo surgical resection for large (> 10 cm3) brain metastases (BMs). Staged SRS requires adaptive planning during each stage of the irradiation period for improved tumor control and reduced radiation damage. However, there has been no study on the tumor reduction rates of this method. We evaluated the outcomes of two-stage SRS across multiple primary cancer types. METHODS: We analyzed 178 patients with 182 large BMs initially treated with two-stage SRS. The primary cancers included breast (BC), non-small cell lung (NSCLC), and gastrointestinal tract cancers (GIC). We analyzed the overall survival (OS), neurological death, systemic death (SD), tumor progression (TP), tumor recurrence (TR), radiation necrosis (RN), and the tumor reduction rate during both stages. RESULTS: The median survival time after the first Gamma Knife surgery (GKS) procedure was 6.6 months. Compared with patients with BC and NSCLC, patients with GIC had shorter OS and a higher incidence of SD. Compared with patients with NSCLC and GIC, patients with BC had significantly higher tumor reduction rates in both sessions. TP rates were similar among primary cancer types. There was no association of the tumor reduction rate with tumor control. The overall cumulative incidence of RN was 4.2%; further, the RN rates were similar among primary cancer types. CONCLUSIONS: Two-stage SRS should be considered for BC and NSCLC if surgical resection is not indicated. For BMs from GIC, staged SRS should be carefully considered and adapted to each unique case given its lower tumor reduction rate and shorter OS.
  • Shogo Furukawa, Shigeki Hirano, Tatsuya Yamamoto, Masato Asahina, Tomoyuki Uchiyama, Yoshitaka Yamanaka, Yoshikazu Nakano, Ai Ishikawa, Kazuho Kojima, Midori Abe, Yuriko Uji, Yoshinori Higuchi, Takuro Horikoshi, Takashi Uno, Satoshi Kuwabara
    Parkinsonism & related disorders 70 60-66 2020年1月  査読有り
    BACKGROUND: Subthalamic nucleus deep brain stimulation (STN DBS) is an established therapy for alleviating motor symptoms in advanced Parkinson's disease (PD) patients; however, a postoperative decline in cognitive and speech function has become problematic although its mechanism remains unclear. The aim of the present study was to elucidate the properties of language and drawing ability and cerebral perfusion in PD patients after bilateral STN DBS surgery. METHODS: Western aphasia battery, including drawing as a subcategory, and perfusion (N-isopropyl-p-[123I] iodoamphetamine) SPECT scan was conducted in 21 consecutive PD patients, before, and three to six months after, bilateral STN DBS surgery while on stimulation. Perfusion images were compared with those of 17 age- and gender-matched healthy volunteers. In the parametric image analysis, the statistical peak threshold was set at P < 0.001 uncorrected with a cluster threshold set at P < 0.05 uncorrected. RESULTS: Although motor symptoms were improved and general cognition was preserved in the patient group, 11 patients (52.4%) showed a decline in the drawing subcategory after surgery, which showed a reduction in Frontal Assessment Battery score in this group of patients. Statistical parametric analysis of the brain perfusion images showed a decrease of cerebral blood flow in the prefrontal and cingulate cortex after surgery. Patients whose drawing ability declined showed decreased perfusion in the middle cingulate cortex comparing before and after surgery. CONCLUSION: Present results show that some PD patients show a decline in drawing ability after bilateral STN DBS which may attributable by dysfunction in the cingulate network.
  • Yakufujiang M, Higuchi Y, Aoyagi K, Yamamoto T, Abe M, Okahara Y, Izumi M, Nagano O, Yamanaka Y, Hirano S, Shiina A, Murata A, Iwadate Y
    Acta neurochirurgica 161(10) 2049-2058 2019年10月  査読有り
  • Serizawa T, Yamamoto M, Higuchi Y, Sato Y, Shuto T, Akabane A, Jokura H, Yomo S, Nagano O, Kawagishi J, Yamanaka K
    Journal of neurosurgery 132(5) 1-10 2019年4月  査読有り
  • Yamamoto M, Higuchi Y, Serizawa T, Kawabe T, Nagano O, Sato Y, Koiso T, Watanabe S, Aiyama H, Kasuya H
    Journal of neurosurgery 129(Suppl1) 77-85 2018年12月  査読有り
  • Serizawa T, Higuchi Y, Yamamoto M, Matsunaga S, Nagano O, Sato Y, Aoyagi K, Yomo S, Koiso T, Hasegawa T, Nakazaki K, Moriki A, Kondoh T, Nagatomo Y, Okamoto H, Kohda Y, Kawai H, Shidoh S, Shibazaki T, Onoue S, Kenai H, Inoue A, Mori H
    Journal of neurosurgery 1-11 2018年9月  査読有り
  • Higuchi Y, Yamamoto M, Serizawa T, Aiyama H, Sato Y, Barfod BE
    Cancer management and research 10 1889-1899 2018年  査読有り筆頭著者
  • Masaaki Yamamoto, Toru Serizawa, Yoshinori Higuchi, Yasunori Sato, Jun Kawagishi, Kazuhiro Yamanaka, Takashi Shuto, Atsuya Akabane, Hidefumi Jokura, Shoji Yomo, Osamu Nagano, Hidefumi Aoyama
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 99(1) 31-40 2017年9月  査読有り
    Purpose: The JLGK0901 study showed the noninferiority of stereotactic radiosurgery (SRS) alone as initial treatment of 5 to 10 brain metastases (BMs) compared with 2 to 4 BMs in terms of overall survival and most secondary endpoints (Lancet Oncol 2014; 15: 387-95). However, observation periods were not long enough to allow confirmation of the long-term safety of SRS alone in patients with 5 to 10 BMs. Methods and Materials: This was a prospective observational study of Gamma Knife SRS-treated patients with 1 to 10 newly diagnosed BMs enrolled at 23 facilities between March 1, 2009, and February 15, 2012. Results: The 1194 eligible patients were categorized into the following groups: group A, 1 tumor (n=455); group B, 2 to 4 tumors (n=531); and group C, 5 to 10 tumors (n=208). Cumulative rates of Mini-Mental State Examination (MMSE) score maintenance (MMSE score decrease &lt;3 from baseline) determined with a competing risk analysis of groups A, B, and C were 93%, 91%, and 92%, respectively, at the 12th month after SRS; 91%, 89%, and 91%, respectively, at the 24th month; 89%, 88%, and 89%, respectively, at the 36th month; and 87%, 86%, and 89%, respectively, at the 48th month (hazard ratio [HR] of group A vs group B, 0.719; 95% confidence interval [CI], 0.437-1.172; PZ. 18; HR of group B vs group C, 1.280; 95% CI, 0.696-2.508; PZ. 43). During observations ranging from 0.3 to 67.5 months (median, 12.0 months; interquartile range, 5.826.5 months), as of December 2014, 145 patients (12.1%) had SRS-induced complications. Cumulative complication incidences by competing risk analysis for groups A, B, and C were 7%, 8%, and 6%, respectively, at the 12th month after SRS; 10%, 11%, and 11%, respectively, at the 24th month; 11%, 11%, and 12%, respectively, at the 36th month; and 12%, 12%, and 13%, respectively, at the 48th month (HR of group A vs group B, 0.850; 95% CI, 0.592-1.220; P=. 38; HR of group B vs group C, 1.052; 95% CI, 0.666-1.662, P=. 83). Leukoencephalopathy occurred in 12 of the 1074 patients (1.1%) with follow-up magnetic resonance imaging and was detected after salvage whole-brain radiation therapy in 11 of these 12 patients. In these 11 patients, leukoencephalopathy was detected by magnetic resonance imaging 5.2 to 21.2 months (median, 11.0 months; interquartile range, 7.0-14.4 months) after whole-brain radiation therapy. Conclusions: Neither MMSE score maintenance nor post-SRS complication incidence differed among groups A, B, and C. This longer-term follow-up study further supports the already-reported noninferiority hypothesis of SRS alone for patients with 5 to 10 BMs versus 2 to 4 BMs. (C) 2017 Elsevier Inc. All rights reserved.
  • Yoshinori Higuchi, Shinji Matsuda, Toru Serizawa
    MOVEMENT DISORDERS 32(1) 28-35 2017年1月  査読有り筆頭著者責任著者
    Functional radiosurgery has advanced steadily during the past half century since the development of the gamma knife technique for treating intractable cancer pain. Applications of radiosurgery for intracranial diseases have increased with a focus on understanding radiobiology. Currently, the use of gamma knife radiosurgery to ablate deep brain structures is not widespread because visualization of the functional targets remains difficult despite the increased availability of advanced neuroimaging technology. Moreover, most existing reports have a small sample size or are retrospective. However, increased experience with intraoperative neurophysiological evaluations in radiofrequency thalamotomy and deep brain stimulation supports anatomical and neurophysiological approaches to the ventralis intermedius nucleus. Two recent prospective studies have promoted the clinical application of functional radiosurgery for movement disorders. For example, unilateral gamma knife thalamotomy is a potential alternative to radiofrequency thalamotomy and deep brain stimulation techniques for intractable tremor patients with contraindications for surgery. Despite the promising efficacy of gamma knife thalamotomy, however, these studies did not include sufficient follow-up to confirm long-term effects. Herein, we review the radiobiology literature, various techniques, and the treatment efficacy of gamma knife radiosurgery for patients with movement disorders. Future research should focus on randomized controlled studies and long-term effects. (C) 2016 International Parkinson and Movement Disorder Society
  • Masaaki Yamamoto, Toru Serizawa, Takashi Shuto, Atsuya Akabane, Yoshinori Higuchi, Jun Kawagishi, Kazuhiro Yamanaka, Yasunori Sato, Hidefumi Jokura, Shoji Yomo, Osamu Nagano, Hiroyuki Kenai, Akihito Moriki, Satoshi Suzuki, Yoshihisa Kida, Yoshiyasu Iwai, Motohiro Hayashi, Hiroaki Onishi, Masazumi Gondo, Mitsuya Sato, Tomohide Akimitsu, Kenji Kubo, Yasuhiro Kikuchi, Toru Shibasaki, Tomoaki Goto, Masami Takanashi, Yoshimasa Mori, Kintomo Takakura, Naokatsu Saeki, Etsuo Kunieda, Hidefumi Aoyama, Suketaka Momoshima, Kazuhiro Tsuchiya
    LANCET ONCOLOGY 15(4) 387-395 2014年4月  査読有り
    Background We aimed to examine whether stereotactic radiosurgery without whole-brain radiotherapy (WBRT) as the initial treatment for patients with five to ten brain metastases is non-inferior to that for patients with two to four brain metastases in terms of overall survival. Methods This prospective observational study enrolled patients with one to ten newly diagnosed brain metastases Clargest tumour &lt; 10 mL in volume and &lt; 3 cm in longest diameter; total cumulative volume &lt;= 15 mL) and a Karnofsky performance status score of 70 or higher from 23 facilities in Japan. Standard stereotactic radiosurgery procedures were used in all patients; tumour volumes smaller than 4 mL were irradiated with 22 Gy at the lesion periphery and those that were 4-10 mL with 20 Gy. The primary endpoint was overall survival, for which the non-inferiority margin for the comparison of outcomes in patients with two to four brain metastases with those of patients with five to ten brain metastases was set as the value of the upper 95% CI for a hazard ratio CHR) of 1. 30, and all data were analysed by intention to treat. The study was finalised Dec 31, 2012, for analysis of the primary endpoint; however, monitoring of stereotactic radiosurgery-induced complications and neurocognitive function assessment will continue for the censored subset until the end of 2014. This study is registered with the University Medical Information Network Clinical Trial Registry, number 000001812. Findings We enrolled 1194 eligible patients between March 1, 2009, and Feb 15, 2012. Median overall survival after stereotactic radiosurgery was 13 . 9 months [95% CI 12 .0- 15 . 6] in the 455 patients with one tumour, 10 . 8 months [9 . 4- 12 . 4] in the 531 patients with two to four tumours, and 10.8 months [9.1- 12.7] in the 208 patients with fi ve to ten tumours. Overall survival did not diff er between the patients with two to four tumours and those with fi ve to ten (HR 0 . 97, 95% CI 0.81- 1.18 [less than non- inferiority margin], p= 0.78; p non- inferiority &lt; 0.001). Stereotactic radiosurgery- induced adverse events occurred in 101 (8%) patients; nine (2%) patients with one tumour had one or more grade 3- 4 event compared with 13 (2%) patients with two to four tumours and six (3%) patients with fi ve to ten tumours. The proportion of patients who had one or more treatment- related adverse event of any grade did not diff er signifi cantly between the two groups of patients with multiple tumours (50 [9%] patients with two to four tumours vs 18 [9%] with fi ve to ten; p= 0.89). Four patients died, mainly of complications relating to stereotactic radiosurgery (two with one tumour and one each in the other two groups). Interpretation Our results suggest that stereotactic radiosurgery without WBRT in patients with five to ten brain metastases is non-inferior to that in patients with two to four brain metastases. Considering the minimal invasiveness of stereotactic radiosurgery and the fewer side-effects than with WBRT, stereotactic radiosurgery might be a suitable alternative for patients with up to ten brain metastases.
  • Eiji Arai, Makoto Arai, Tomoyuki Uchiyama, Yoshinori Higuchi, Kyoko Aoyagi, Yoshitaka Yamanaka, Tatsuya Yamamoto, Osamu Nagano, Akihiro Shiina, Daisuke Maruoka, Tomoaki Matsumura, Tomoo Nakagawa, Tatsuro Katsuno, Fumio Imazeki, Naokatsu Saeki, Satoshi Kuwabara, Osamu Yokosuka
    BRAIN 135(Pt 5) 1478-1485 2012年5月  査読有り
    It is established that deep brain stimulation of the subthalamic nucleus improves motor function in advanced Parkinson's disease, but its effects on autonomic function remain to be elucidated. The present study was undertaken to investigate the effects of subthalamic deep brain stimulation on gastric emptying. A total of 16 patients with Parkinson's disease who underwent bilateral subthalamic deep brain stimulation were enrolled. Gastric emptying was expressed as the peak time of (CO2)-C-13 excretion (T-max) in the C-13-acetate breath test and was assessed in patients with and without administration of 100-150 mg levodopa/decarboxylase inhibitor before surgery, and with and without subthalamic deep brain stimulation at 3 months post-surgery. The pattern of (CO2)-C-13 excretion curve was analysed. To evaluate potential factors related to the effect of subthalamic deep brain stimulation on gastric emptying, we also examined the association between gastric emptying, clinical characteristics, the equivalent dose of levodopa and serum ghrelin levels. The peak time of (CO2)-C-13 excretion (T-max) values for gastric emptying in patients without and with levodopa/decarboxylase inhibitor treatment were 45.6 +/- 22.7 min and 42.5 +/- 13.6 min, respectively (P = not significant), thus demonstrating levodopa resistance. The peak time of (CO2)-C-13 excretion (T-max) values without and with subthalamic deep brain stimulation after surgery were 44.0 +/- 17.5 min and 30.0 +/- 12.5 min (P &lt; 0.001), respectively, which showed that subthalamic deep brain stimulation was effective. Simultaneously, the pattern of the (CO2)-C-13 excretion curve was also significantly improved relative to surgery with no stimulation (P = 0.002), although the difference with and without levodopa/decarboxylase inhibitor was not significant. The difference in peak time of (CO2)-C-13 excretion (T-max) values without levodopa/decarboxylase inhibitor before surgery and without levodopa/decarboxylase inhibitor and subthalamic deep brain stimulation after surgery was not significant, although motor dysfunction improved and the levodopa equivalent dose decreased after surgery. There was little association between changes in ghrelin levels (delta ghrelin) and changes in T-max values (delta T-max) in the subthalamic deep brain stimulation trial after surgery (r = -0.20), and no association between changes in other characteristics and delta T-max post-surgery in the subthalamic deep brain stimulation trial. These results showed that levodopa/decarboxylase inhibitor did not influence gastric emptying and that subthalamic deep brain stimulation can improve the dysfunction in patients with Parkinson's disease possibly by altering the neural system that controls gastrointestinal function after subthalamic deep brain stimulation. This is the first report to show the effectiveness of subthalamic deep brain stimulation on gastrointestinal dysfunction as a non-motor symptom in Parkinson's disease.
  • Robert D. Pearlstein, Yoshinori Higuchi, Maria Moldovan, Kwame Johnson, Shiro Fukuda, Daila S. Gridley, James D. Crapo, David S. Warner, James M. Slater
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY 86(2) 145-163 2010年2月  査読有り
    Purpose: We examined the effects of manganese (III) meso-tetrakis (dicthyl-2-5-imidazole) porphyrin, a metalloporphyrin antioxidant (MPA), on neural tissue radiation toxicity in vivo and on tumour cell radiosensitivity in vitro. Materials and methods: MPA was administered directly into the right lateral ventricle of young adult, male Sprague-Dawley rats (0 or 3.4 mu g) 3 h before treatment with a single fraction, 100 Gy radiation dose delivered to the left brain hemisphere. The effects of treatment on radiation responses were assessed at different time points following irradiation. Results: MPA treatment prior to brain irradiation protected against acute radiation-induced apoptosis and ameliorated delayed damage to the blood-brain barrier and radiation necrosis, but without producing a discernible increase in tissue superoxide disumtase (SOD) activity. In vitro, MPA pretreatment protected against radiation-induced apoptosis in primary neuronal cultures and increased clonogenic survival of irradiated rat glioma C6 cells, but had no discernible effect on radiation-induced DNA double-strand breaks. MPA, a low molecular weight SOD mimic, significantly increased mitochondrial SOD activity in C6 cells, but not total cellular SOD activity. MPA up-regulated C6 expression of heme-oxygenase I (HO-1), an endogenous radioprotectant, but had no effect on HO-I levels in human astrocytoma U-251 cells, human prostatic carcinoma LNCaP cells, or primary rat brain microvascular endothelial cells in vitro, nor on brain tissue HO-I expression levels in vivo. Conclusions: Metalloporphyrin antioxidants merit further exploration as adjunctive radioprotectants for cranial radiotherapy/radiosurgery applications, although the potential for tumour protection must be carefully considered.
  • Yoshinori Higuchi, Toru Serizawa, Osamu Nagano, Shinji Matsuda, Junichi Ono, Makoto Sato, Yasuo Iwadate, Naokatsu Saeki
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 74(5) 1543-1548 2009年8月  査読有り筆頭著者責任著者
    Purpose: To evaluate the efficacy and toxicity of staged stereotactic radiotherapy with a 2-week interfraction interval for unresectable brain metastases more than 10 cm(3) in volume. Patients and Methods: Subjects included 43 patients (24 men and 19 women), ranging in age from 41 to 84 years, who had large brain metastases (&gt; 10 cc in volume). Primary tumors were in the colon in 14 patients, lung in 12, breast in 11, and other in 6. The peripheral dose was 10 Gy in three fractions. The interval between fractions was 2 weeks. The mean tumor volume before treatment was 17.6 +/- 6.3 cm(3) (mean +/- SD). Mean follow-up interval was 7.8 months. The local tumor control rate, as well as overall, neurological, and qualitative survivals, were calculated using the Kaplan-Meier method. Results: At the time of the second and third fractions, mean tumor volumes were 14.3 +/- 6.5 (18.8% reduction) and 10.6 +/- 6.1 cm(3) (39.8% reduction), respectively, showing significant reductions. The median overall survival period was 8.8 months. Neurological and qualitative survivals at 12 months were 81.8% and 76.2%, respectively. Local tumor control rates were 89.8% and 75.9% at 6 and 12 months, respectively. Tumor recurrence-free and symptomatic edema-free rates at 12 months were 80.7% and 84.4%, respectively. Conclusions: The 2-week interval allowed significant reduction of the treatment volume. Our results suggest staged stereotactic radiotherapy using our protocol to be a possible alternative for treating large brain metastases. (C) 2009 Elsevier Inc.
  • Osamu Nagano, Yoshinori Higuchi, Toru Serizawa, Junichi Ono, Shinji Matsuda, Iwao Yamakami, Naokatsu Saeki
    JOURNAL OF NEUROSURGERY 109(5) 811-816 2008年11月  査読有り
    Object. The authors prospectively analyzed volume changes in vestibular schwannomas (VSs) after stereotactic radiosurgery. Methods. One hundred Consecutive patients with unilateral VS treated with Gamma Knife Surgery (GKS) at Chiba Cardiovascular Center between 1998 and 2006 were analyzed in this study. For each lesion the Gd-enhanced volume was measured serially every 3 months in the 1st year, then every 6 months thereafter, using volumetric software. The frequency and degree of transient tumor expansion were documented and possible prognostic factors were analyzed. Concurrently, neurological deterioration involving trigeminal, facial, and cochlear nerve functions were also assessed. Results. The mean observation period was 65 months (range 25-100 months). There were 32 men and 68 women whose mean age was 59.1 years (range 29-80 years). Tumor volumes at GKS averaged 2.7 cm(3) (range 0.1-13.2 C 113), and the lesions were irradiated at the mean 52.2% isodose line for the tumor margin (range 50-67%), with a mean dose of 12.2 Gy (range 10.5-13 Gy) at the periphery. The tumor Volume was increased by 23% at 3 months and 27% at 6 months. Tumors shrank to their initial size over a mean period of 12 months. The maximum volume increase was &lt; 10% (no significant increase) in 26 patients, 10-30% in 23, 30-50% in 22, 50-100% in 16, and &gt; 100% in 13. The peak tumor expansion averaged 47% (range 0-613%). A high-dose (&gt;= 3.5 Gy/min) treatment appears to be the greatest risk factor for transient tumor expansion, although the difference did not reach statistical significance. Transient facial palsy and facial dysesthesia correlated strongly with tumor expansion, but only half of the hearing loss was coincident with this phenomenon. Conclusions. Transient expansion of VSs after GKS was found to be much more frequent than previously reported, strongly Suggesting a correlation with deterioration of facial and trigeminal nerve functions.
  • Y Higuchi, Y Iwadate, A Yamaura
    NEUROLOGY 63(12) 2384-2386 2004年12月  査読有り
    The authors prospectively treated 18 consecutive patients with low-grade oligodendroglial tumors without postoperative radiotherapy. The treatment strategy was as follows: follow-up after total resection and chemotherapy after subtotal resection or biopsy. All patients were alive and 17 patients (94%) were progression-free after a median follow-up of 4.7 years. The results suggested that radiotherapy could be postponed until clinical progression in the treatment of low-grade oligodendroglial tumors.
  • Y Higuchi, RP Iacono
    NEUROSURGERY 52(3) 558-568 2003年3月  査読有り
    OBJECTIVE: To investigate the potential operative morbidity in posteroventral pallidotomy (PVP) for patients with Parkinson's disease. METHODS: We designed a retrospective study that included 796 consecutive patients (mean age, 64.9 yr; male, 559; female, 237) with Parkinson's disease. All PVPs (simultaneous bilateral PVP, n = 272; sequential bilateral PVP, n = 88; unilateral PVP, n = 436) were performed during a 7-year period. The total number of operations was 884, and the number of PVP procedures was 1156. In 108 patients, ventral diate nucleus thalamotomy was performed simultaneously. RESULTS: The overall complication rate, including temporary problems, was 15.3% of 884 operations. Permanent complications occurred in 3.6% of total operations. Intracranial hemorrhage occurred in 24 operations (2.7%). In seven of them, the patients required craniotomy and hematoma evacuation and sustained a disabling motor deficit (0.8%). Intracranial hemorrhage occurred more often in patients who underwent microelectrode recording and had a history of chronic hypertension. Hemiparesis without intracranial hematoma occurred in 12 operations (1.4%). Microelectrode-recording was a risk factor for postoperative hemiparesis without hemorrhage.)n 19 operations (2.1%), patients developed a partial visual field deficit. Speech disturbance after surgery was observed in 23 operations (2.6%) but resolved in 17 by 1 week after 1 surgery. In 55 operations (6.2%), patients developed postoperative confusion. This occurred more often in elderly patients and those with advanced disease. In 17 operations (1.9%), patients required observation in the intensive care unit because of postoperative hypotension. CONCLUSION: Complications from stereotactic pallidotomy were not frequent. ever, the residual symptoms from complications can be serious in many cases.
  • MJ McGirt, A Parra, HX Sheng, Y Higuchi, TD Oury, DT Laskowitz, RD Pearlstein, DS Warner
    STROKE 33(9) 2317-2323 2002年9月  査読有り
    Background and Purpose-Subarachnoid hemorrhage (SAH) increases production of vascular extracellular superoxide anion (O-2(-)) We examined whether overexpression of murine extracellular superoxide dismutase (EC SOD) alters SAH induced cerebral vasospasm oxidative stress and neurological outcome Methods-Mice exhibiting a 2 fold increase in vascular EC SOD and wild type (WT) littermates were subjected to sham surgery or SAH by perforation of the right anterior cerebral artery Neurological deficits were scored 72 hours later Middle cerebral artery (MCA) diameter was measured or immunohistochemically stained for nitrotyrosine Results-MCA diameter (mean+/-SD) was greater in EC SOD versus WT mice after SAH but not sham surgery (EC SOD SAH=56+/-10 mum WT SAH=38+/-13 mum [P&lt;0 01] EC SOD sham=99+/-16 &mu;m WT sham=100+/-15 &mu;m) SAH decreased median (range) neurological score (scoring scale 9 to 39 no deficit=39) versus shams but there was no difference between EC SOD and WT groups (EC SOD SAH=26 [23 to 30] WT SAH=23 [19 to 29] [P=0 27] EC SOD sham=39 [39] WT sham=39 [39]) Sensory motor deficits correlated with MCA diameter (P&lt;0 001) but worsened primarily between 60 and 50 mum plateauing below this threshold The percentage of mice with MCA nitrotyrosine staining increased after SAH in WT (sham=29% SAH=100% [P&lt;0 05]) but not EC SOD (sham=33% SAH=44% [P=0 80]) mice Conclusions-Endogenous overexpression of EC SOD attenuated vasospasm and oxidative stress but failed to reduce neurological deficits after SAH Extracellular O-2(-) likely plays a direct role in the etiology of vasospasm.

MISC

 326

講演・口頭発表等

 33

担当経験のある科目(授業)

 5